Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Agilent Technologies Inc. (NYSE: A) has partnered with SGS to develop the SGS AXYS Method 16130, a new gas chromatography/tandem mass spectrometry method approved by the US EPA for analyzing dioxins. This method addresses the limitations of the older EPA 1613B method, which relied on outdated technology. The new method enhances testing accuracy and lowers operational costs, empowering more laboratories to conduct essential environmental testing. This collaboration marks a significant step in Agilent's commitment to environmental health and safety.
Agilent Technologies (NYSE: A) will announce its fourth-quarter fiscal year 2020 financial results on November 23, after market close. A live webcast of the investor conference call will follow. Additionally, the company has scheduled a virtual Analyst and Investor meeting on December 9, where senior management will discuss strategies for enhancing revenue growth and shareholder value, including a live Q&A session. Agilent generated $5.16 billion in revenue in fiscal 2019, employing 16,300 people globally.
Summary not available.
Agilent Technologies Inc. (NYSE: A) has been awarded the 2020 R&D 100 Award for its innovative Vaya Raman raw material identity verification system, recognized in the Analytical/Test category. This handheld spectrometer employs spatially offset Raman spectroscopy (SORS) technology to swiftly identify raw materials while addressing compliance with stringent regulations in the pharmaceutical sector. Launched in March 2020, it enhances testing protocols, allowing for effective identification through various container types, thus improving productivity for users.
Agilent Technologies has expanded Visiopharm’s validated image analysis algorithm to include HercepTest™ mAb pharmDx for Dako Omnis, now CE-IVD marked and available in Europe. This integration allows pathologists to utilize the Visiopharm HER2 APP for more objective assessments of HER2 staining in breast cancer tissue. The algorithm aims to enhance diagnosis accuracy and save time, potentially benefiting patient outcomes by streamlining case management. This advancement represents a significant step towards improving tissue diagnostics efficiency in pathology labs.
MOBILion Systems, Inc., based in Chadds Ford, Pa., announced a successful $35 million Series B funding round led by aMoon, with participation from existing investors including Agilent Technologies (NYSE: A). The funds will support the commercial launch of their Structures for Lossless Ion Manipulation (SLIM) technology aimed at enhancing biomarker discovery and diagnostics. The first product is set for full launch in North America in 2021. MOBILion's SLIM technology is expected to improve the characterization of biologic therapeutics and contribute to COVID-19 research.